drugset / Trial / NCT06238635
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to determine how effective dostarlimab in combination with cobolimab is in metastatic or recurrent cervical cancer.
Timeline
- Start
- 2024-03-11
- Primary completion
- 2026-12-01
- Completion
- 2027-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobolimab | Monoclonal antibody | — | Intravenous |
| Subject | Dostarlimab | Monoclonal antibody | — | Intravenous |